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Supplementary Fig. 1. MELD score changes between baseline to month 6 and 
month 15. Top panel shows MELD change at month 6 (282 comparative scores 
available) and bottom panel shows MELD change at month 15 (74 comparative scores 
available – MELD at month 15 was calculated if laboratory results were available within 
a two month window of month 15). Patients transplanted at month 6 and 15 respectively 
were excluded.  
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Supplementary table 1. Virological outcome (intention to treat) by treatment 
regime and genotype 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All   N SVR24 (%) 
Virological 
failure (%) 
Died before SVR 
24(%) 
Not available / lost 
to follow up (%) 
G1 Sof/LDV 13 76.9 7.7 15.4 0.0 
  Sof/LDV/RBV 148 89.2 5.4 3.4 2.0 
  Sof/DCV 3 66.7 33.3 0.0 0.0 
  Sof/DCV/RBV 34 88.2 2.9 2.9 5.9 
G3 Sof/LDV 5 40.0 60.0 0.0 0.0 
  Sof/LDV/RBV 57 61.4 33.3 5.3 0.0 
  Sof/DCV 5 40.0 0.0 60.0 0.0 
  Sof/DCV/RBV 104 69.2 16.3 10.6 3.8 
Other 
genotypes Sof/LDV 0 0.0 0.0 0.0 0.0 
  Sof/LDV/RBV 23 87.0 13.0 0.0 0.0 
  Sof/DCV 3 100.0 0.0 0.0 0.0 
  Sof/DCV/RBV 11 81.8 0.0 9.1 9.1 
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Supplementary table 2. Serious adverse events in treated patients. Events after 
month 6 were reported only for patients who achieved SVR24, since non-SVR24 
patients received retreatment. Note each patient may be counted more than once if 
multiple events occurred.  
 
 
 SVR24 (n=317) Non-SVR24 (n=89) 
 Month 0-6 Month 6-15 Month 0-15 Month 0-6   
Decompensation 46 (14.5%) 16 (5.0%) 52(16.4%) 26 (29.2%) - - 
Sepsis 21 (6.6%) 9 (2.8%) 26 (8.2%) 6 (6.7%) - - 
All cause 
hospitalisations 
94 (29.7%) 62 (19.6%) 116 (36.6%) 39 (43.8%) - - 
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Supplementary table 3. Outcomes within 6 months in patients after excluding 
active alcohol users at baseline. ** difference between treated and untreated p=0.025 
 
 N Deaths Hepatocellular 
carcinoma  
Liver 
transplants 
Decompensation 
Treated 353 12 (3.4%) 15 (4.2%) 27 (7.6%) 66 (18.7%) * 
Untreated 201 9 (4.5%) 9 (4.5%) 10 (5.0%) 54 (26.9%) * 
Untreated – 
subsequently 
received DAA 
106 0 (0.0%) 4 (3.8%) 3 (2.8%) 26 (24.5%) 
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Supplementary table 4. MELD score change at month 6 and 15 according to 
baseline MELD, for patients with SVR24 who did not receive a transplant during 
this period.  
 
Baseline 
MELD 
N Average 
MELD – 
baseline 
Average MELD 
change – month 6 
(range) 
Average 
MELD  – 
month 6 
Average MELD 
change – 
month 15 
Average 
MELD  – 
month 15 
</= 9 87 8.3 +1.8 (-2 to 5) 8.0 +0.74 (-2 to 4) 8.5 
10-14 166 11.8 - 0.77 (-6 to 7) 10.9 +0.71 (-6 to 10) 12.2 
>15 45 17 -2.7 (-12 to 4) 14.7 - 1.4 (-7 to 10) 15.0 
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Supplementary table 5. MELD score change at month 15 according to baseline 
MELD, for patients with SVR24 who did not receive a transplant during this period.  
 
 Month 15 (n, %) 
Baseline </=9 10-14 >15 
</=9 (n=26) 19 (73.1%) 7 (26.9%) 0 (0%) 
10-14 (n=41) 10 (24.4%) 20 (48.8%) 11 (26.8%) 
>15 (n=7) 1 (14.3%) 3 (42.9%) 3 (42.9%) 
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